Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 2 December 2008, doi:10.1136/bmj.a2788
Cite this as: BMJ 2008;337:a2788
| The first 100% of the full text of this article appears below. |
Sathasivam and Lecky say that lipophilic statins (simvastatin, atorvastatin, lovastatin) are more likely to produce muscular effects than are relatively hydrophilic agents (pravastatin, rosuvastatin, fluvastatin).1
However, simvastatin, atorvastatin, and lovastatin are metabolised by the hepatic cytochrome P450 3A4 (CYP3A4) enzyme system whereas pravastatin, fluvastatin, and rosuvastatin do not rely on CYP3A4. This is especially important in patients with a renal transplant (and other transplants and other conditions) who are receiving immunosuppressive drugs and also require a statin. CYP3A4 metabolises ciclosporin, tacrolimus, and sirolimus. As highlighted in box 1,1 increased statin concentrations occur with ciclosporin treatment, increasing the risk of myopathy.
The maximum dose of statin with ciclosporin according to product information is simvastatin 10 mg, atorvastatin 10 mg, pravastatin 20 mg increasing to 40 mg; caution is advised wih fluvastatin, and rosuvastatin is contraindicated.
Cite this as: BMJ 2008;337:a2788
Brian Camilleri, consultant nephrologist1
1 Ipswich Hospital NHS Trust, Ipswich IP4 5PD
brian.camilleri@ipswichhospital.nhs.uk
Read all Rapid Responses